Clinical Trials

Genentech will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today...

AstraZeneca today announced the creation of a Scientific Review Board that will act independently to assess requests from external researchers which include patient level data. The Board of independent clinicians and academics has been established as part of AstraZeneca’s...

UCB is committed to providing the opportunity to patients to make informed decisions about participating in clinical trials. UCB is committed to increasing transparency relating to the existence and results of sponsored clinical studies. In light...

Roche is committed to sharing data from clinical trials and has registered and posted summary reports for trials involving patients on clinicaltrials.gov and on roche-trials.com since 2005. Alongside this posting, we actively seek presentation and publication of our clinical...

The Astellas Group (*1) (hereinafter collectively “Astellas”) recognises that making clinical trial information and results more widely available to researchers, healthcare professionals, patients, and interested members of the public will benefit public health. Therefore, Astellas is committed to publicly...

Valeant Pharmaceuticals International, Inc.’s  wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for VESNEO™ (latanoprostene bunod ophthalmic solution 0.024%), an...

CTI BioPharma Corp.  announced its plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) following a productive pre-NDA meeting for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1...